You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVerapamil
Accession NumberDB00661  (APRD00335)
TypeSmall Molecule
GroupsApproved
DescriptionA calcium channel blocker that is a class IV anti-arrhythmia agent. [PubChem]
Structure
Thumb
Synonyms
Calan
Calan sr
Covera-hs
CP-16533-1
CP-165331
D-365
Iproveratril
Isoptin
Isoptin sr
Tarka
Vérapamil
Verapamil
Verapamilo
Verapamilum
Verelan
External Identifiers
  • CP 16533-1
  • D 365
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-verapamil - 120mgtablet120 mgoralAltimed Pharma Inc.1990-12-312004-08-03Canada
Alti-verapamil - 80mgtablet80 mgoralAltimed Pharma Inc.1990-12-312004-08-03Canada
Calantablet, film coated80 mg/1oralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs
Calantablet, film coated120 mg/1oralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs
Calan SRtablet, film coated, extended release180 mg/1oralG.D. Searle LLC Division of Pfizer Inc1989-12-15Not applicableUs
Calan SRtablet, film coated, extended release240 mg/1oralG.D. Searle LLC Division of Pfizer Inc1986-12-16Not applicableUs
Calan SRtablet, film coated, extended release120 mg/1oralG.D. Searle LLC Division of Pfizer Inc1991-03-06Not applicableUs
Covera-HStablet, extended release180 mg/1oralG.D. Searle LLC Division of Pfizer Inc1996-02-26Not applicableUs
Covera-HStablet (extended-release)180 mgoralPfizer Canada Inc1997-11-132013-02-15Canada
Covera-HStablet, extended release240 mg/1oralG.D. Searle LLC Division of Pfizer Inc1996-02-26Not applicableUs
Covera-HStablet (extended-release)240 mgoralPfizer Canada Inc1997-11-132013-02-15Canada
Dom-verapamil SR 240mg Tabletstablet (extended-release)240 mgoralDominion Pharmacal1999-12-16Not applicableCanada
Isoptin Inj 2.5mg/mlliquid2.5 mgintravenousAbbott Laboratories, Limited1984-12-312007-07-31Canada
Isoptin SRtablet (extended-release)240 mgoralBgp Pharma Ulc1988-12-31Not applicableCanada
Isoptin SRtablet (extended-release)180 mgoralBgp Pharma Ulc1994-04-21Not applicableCanada
Isoptin SRtablet (extended-release)120 mgoralBgp Pharma Ulc1991-12-31Not applicableCanada
Isoptin Tab 120mgtablet120 mgoralAbbott Laboratories, Limited1982-12-312007-07-31Canada
Isoptin Tab 80mgtablet80 mgoralAbbott Laboratories, Limited1982-12-312007-07-31Canada
Med Verapamil Tabletstablet80 mgoralMedican Pharma Incorporated1999-03-082011-03-29Canada
Med Verapamil Tabletstablet120 mgoralMedican Pharma Incorporated1999-03-082011-03-29Canada
Mylan-verapamiltablet80 mgoralMylan Pharmaceuticals Ulc1998-05-25Not applicableCanada
Mylan-verapamiltablet120 mgoralMylan Pharmaceuticals Ulc1998-05-11Not applicableCanada
Mylan-verapamil SRtablet (extended-release)120 mgoralMylan Pharmaceuticals Ulc1996-12-31Not applicableCanada
Mylan-verapamil SRtablet (extended-release)120 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-verapamil SRtablet (extended-release)180 mgoralMylan Pharmaceuticals Ulc2016-06-29Not applicableCanada
Mylan-verapamil SRtablet (extended-release)240 mgoralMylan Pharmaceuticals Ulc1996-12-31Not applicableCanada
Mylan-verapamil SRtablet (extended-release)240 mgoralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-verapamil SRtablet (extended-release)180 mgoralMylan Pharmaceuticals Ulc1996-12-312016-06-29Canada
Novo-veramiltablet80 mgoralTeva Canada Limited1989-12-31Not applicableCanada
Novo-veramiltablet120 mgoralTeva Canada Limited1989-12-31Not applicableCanada
Novo-veramil SRtablet (extended-release)240 mgoralTeva Canada Limited1996-12-31Not applicableCanada
Nu-verap SRtablet (extended-release)120 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-verap SRtablet (extended-release)180 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-verap SRtablet (extended-release)240 mgoralNu Pharm Inc2004-07-192012-09-04Canada
Nu-verap Tab 120mgtablet120 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-verap Tab 80mgtablet80 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Penta-verapamil - 120mgtablet120 mgoralPentapharm Ltd.1997-06-252004-07-30Canada
Penta-verapamil - 80mgtablet80 mgoralPentapharm Ltd.1997-06-252004-07-30Canada
PHL-verapamil SRtablet (extended-release)240 mgoralPharmel Inc2002-05-31Not applicableCanada
PMS-verapamil SRtablet (extended-release)240 mgoralPharmascience Inc1999-09-01Not applicableCanada
Pro-verapamil SRtablet (extended-release)120 mgoralPro Doc Limitee2009-06-15Not applicableCanada
Pro-verapamil SRtablet (extended-release)180 mgoralPro Doc Limitee2009-06-15Not applicableCanada
Pro-verapamil SRtablet (extended-release)240 mgoralPro Doc Limitee2008-07-09Not applicableCanada
Riva-verapamil SRtablet (extended-release)240 mgoralLaboratoire Riva Inc2005-09-14Not applicableCanada
Taro-verapamil Tab 120mgtablet120 mgoralTaro Pharmaceuticals Inc1993-12-312000-08-31Canada
Taro-verapamil Tab 80mgtablet80 mgoralTaro Pharmaceuticals Inc1993-12-312000-08-31Canada
Verapamil Hydrochlorideinjection2.5 mg/mLintravenousExela Pharma Sciences, LLC2016-04-22Not applicableUs
Verapamil Hydrochloridecapsule, delayed release pellets360 mg/1oralPhysicians Total Care, Inc.2009-02-12Not applicableUs
Verapamil Hydrochloridecapsule, delayed release pellets180 mg/1oralActavis Pharma, Inc.1990-05-29Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil Hydrochloridecapsule, delayed release pellets360 mg/1oralbryant ranch prepack1990-05-29Not applicableUs
Verapamil Hydrochloridecapsule, extended release100 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verapamil Hydrochloridecapsule, delayed release pellets240 mg/1oralActavis Pharma, Inc.1990-05-29Not applicableUs
Verapamil Hydrochloridecapsule, delayed release pellets120 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-24Not applicableUs
Verapamil Hydrochloridecapsule, extended release200 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verapamil Hydrochloridecapsule, delayed release pellets360 mg/1oralActavis Pharma, Inc.1990-05-29Not applicableUs
Verapamil Hydrochloridecapsule, delayed release pellets180 mg/1oralCarilion Materials Management1990-05-29Not applicableUs
Verapamil Hydrochloridecapsule, extended release300 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil Hydrochloridecapsule, delayed release pellets120 mg/1oralActavis Pharma, Inc.1990-05-29Not applicableUs
Verapamil Hydrochloride Injection 2.5mg/mlsolution2.5 mgintravenousHospira Healthcare Corporation1994-12-31Not applicableCanada
Verapamil Hydrochloride Injection USPliquid2.5 mgintravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Verapamil Injection 2.5mg/mlliquid2.5 mgintravenousNovopharm Limited1994-12-312005-08-10Canada
Verapamil SRtablet (extended-release)240 mgoralSorres Pharma Inc2009-06-222014-06-20Canada
Verapamil Tab 80mgtablet80 mgoralPro Doc Limitee1990-12-312012-07-23Canada
Verapamil-120 Tabtablet120 mgoralPro Doc Limitee1990-12-312009-07-23Canada
Verelancapsule, delayed release pellets180 mg/1oralUCB, Inc.1990-05-29Not applicableUs
Verelancapsule (sustained-release)240 mgoralRecro Gainesville Llc1994-12-31Not applicableCanada
Verelancapsule, delayed release pellets180 mg/1oralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs
Verelancapsule, delayed release pellets120 mg/1oralUCB, Inc.1990-05-29Not applicableUs
Verelancapsule (sustained-release)180 mgoralRecro Gainesville Llc1994-12-31Not applicableCanada
Verelancapsule, delayed release pellets240 mg/1oralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs
Verelancapsule, delayed release pellets240 mg/1oralPhysicians Total Care, Inc.2004-08-12Not applicableUs
Verelancapsule (sustained-release)120 mgoralRecro Gainesville Llc1994-12-31Not applicableCanada
Verelancapsule, delayed release pellets240 mg/1oralUCB, Inc.1990-05-29Not applicableUs
Verelancapsule, delayed release pellets360 mg/1oralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs
Verelancapsule, delayed release pellets360 mg/1oralPhysicians Total Care, Inc.2003-06-12Not applicableUs
Verelancapsule, delayed release pellets360 mg/1oralUCB, Inc.1990-05-29Not applicableUs
Verelancapsule, delayed release pellets120 mg/1oralKremers Urban Pharmaceuticals Inc.1990-05-29Not applicableUs
Verelan PMcapsule, extended release100 mg/1oralUCB, Inc.1998-11-25Not applicableUs
Verelan PMcapsule, extended release100 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verelan PMcapsule, extended release200 mg/1oralUCB, Inc.1998-11-25Not applicableUs
Verelan PMcapsule, extended release200 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verelan PMcapsule, extended release300 mg/1oralUCB, Inc.1998-11-25Not applicableUs
Verelan PMcapsule, extended release300 mg/1oralKremers Urban Pharmaceuticals Inc.1998-11-25Not applicableUs
Verelan PMcapsule, extended release300 mg/1oralbryant ranch prepack1998-11-25Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-verap SRtablet (extended-release)240 mgoralApotex Inc2003-04-24Not applicableCanada
Apo-verap SRtablet (extended-release)120 mgoralApotex Inc2003-04-24Not applicableCanada
Apo-verap SRtablet (extended-release)180 mgoralApotex Inc2003-04-24Not applicableCanada
Apo-verap Tab 80mgtablet80 mgoralApotex Inc1989-12-31Not applicableCanada
Apo-verap Tablet 120mgtablet120 mgoralApotex Inc1989-12-31Not applicableCanada
Verapamiltablet, film coated, extended release180 mg/1oralAmerican Health Packaging2014-01-142015-12-31Us
Verapamiltablet, film coated, extended release240 mg/1oralAmerican Health Packaging2014-01-14Not applicableUs
Verapamiltablet, film coated, extended release120 mg/1oralApotex Corp.2012-11-19Not applicableUs
Verapamiltablet, film coated, extended release180 mg/1oralSt Marys Medical Park Pharmacy2013-02-05Not applicableUs
Verapamiltablet, film coated, extended release180 mg/1oralUnit Dose Services2012-11-19Not applicableUs
Verapamiltablet, film coated, extended release180 mg/1oralApotex Corp.2012-11-19Not applicableUs
Verapamiltablet, film coated, extended release120 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Verapamiltablet, extended release180 mg/1oralPd Rx Pharmaceuticals, Inc.2011-08-05Not applicableUs
Verapamiltablet, film coated, extended release240 mg/1oralApotex Corp.2012-11-19Not applicableUs
Verapamiltablet, film coated, extended release120 mg/1oralAmerican Health Packaging2014-01-142016-03-31Us
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralPd Rx Pharmaceuticals, Inc.2009-09-17Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralSt Marys Medical Park Pharmacy2013-05-22Not applicableUs
Verapamil Hydrochloridecapsule, extended release120 mg/1oralREMEDYREPACK INC.2010-11-22Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralMylan Pharmaceuticals Inc.1997-09-22Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralMajor Pharmaceuticals1986-10-01Not applicableUs
Verapamil Hydrochloridetablet, extended release240 mg/301oralNorthwind Pharmaceuticals2014-05-27Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralPhysicians Total Care, Inc.1996-02-05Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralCardinal Health2009-09-17Not applicableUs
Verapamil Hydrochloridetablet, film coated80 mg/1oralClinical Solutions Wholesale1986-10-01Not applicableUs
Verapamil Hydrochloridetablet120 mg/1oralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs
Verapamil Hydrochloridetablet, film coated40 mg/1oralActavis Pharma, Inc.1993-06-29Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralTeva Pharmaceuticals USA Inc2014-03-10Not applicableUs
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousHospira, Inc.1987-05-06Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralUnit Dose Services2009-09-17Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralbryant ranch prepack2010-04-20Not applicableUs
Verapamil Hydrochloridetablet, extended release180 mg/1oralREMEDYREPACK INC.2011-08-24Not applicableUs
Verapamil Hydrochloridecapsule, extended release120 mg/1oralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs
Verapamil Hydrochloridetablet80 mg/1oralRebel Distributors Corp1995-04-24Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralREMEDYREPACK INC.2013-05-15Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralPhysicians Total Care, Inc.2000-11-28Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralClinical Solutions Wholesale2011-08-05Not applicableUs
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousCardinal Health2011-03-25Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralGlenmark Pharmaceuticals Inc., Usa2011-08-05Not applicableUs
Verapamil Hydrochloridetablet, extended release240 mg/1oralPd Rx Pharmaceuticals, Inc.2012-01-01Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralMylan Pharmaceuticals Inc.2012-08-15Not applicableUs
Verapamil Hydrochloridetablet, film coated80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-10-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralMylan Institutional Inc.1998-04-17Not applicableUs
Verapamil Hydrochloridetablet, extended release180 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralPhysicians Total Care, Inc.2000-05-09Not applicableUs
Verapamil Hydrochloridetablet, extended release120 mg/1oralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs
Verapamil Hydrochloridetablet, extended release180 mg/1oralREMEDYREPACK INC.2011-07-25Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralBlenheim Pharmacal, Inc.2011-02-15Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralREMEDYREPACK INC.2013-03-14Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousCardinal Health2011-03-25Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralGolden State Medical Supply, Inc2014-12-04Not applicableUs
Verapamil Hydrochloridetablet, film coated40 mg/1oralCarilion Materials Management1993-06-29Not applicableUs
Verapamil Hydrochloridetablet40 mg/1oralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralTeva Pharmaceuticals USA Inc2014-01-29Not applicableUs
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousHospira, Inc.1998-10-20Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralClinical Solutions Wholesale1986-10-01Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralbryant ranch prepack1986-10-01Not applicableUs
Verapamil Hydrochloridetablet80 mg/1oralREMEDYREPACK INC.2011-11-16Not applicableUs
Verapamil Hydrochloridecapsule, extended release180 mg/1oralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs
Verapamil Hydrochloridetablet120 mg/1oralRebel Distributors Corp1996-02-05Not applicableUs
Verapamil Hydrochloridetablet120 mg/1oralREMEDYREPACK INC.2014-06-27Not applicableUs
Verapamil Hydrochloridecapsule, extended release300 mg/1oralPhysicians Total Care, Inc.2007-12-20Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Verapamil Hydrochloridetablet, extended release240 mg/1oralPreferred Pharmaceuticals, Inc.2013-09-26Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralAphena Pharma Solutions Tennessee, Llc1997-09-22Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralMylan Pharmaceuticals Inc.1996-03-25Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-10-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralMylan Institutional Inc.1998-11-15Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralA S Medication Solutions Llc1986-10-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralBlenheim Pharmacal, Inc.2010-08-20Not applicableUs
Verapamil Hydrochloridetablet240 mg/1oralREMEDYREPACK INC.2012-10-02Not applicableUs
Verapamil Hydrochloridecapsule, extended release100 mg/1oralPhysicians Total Care, Inc.2008-08-07Not applicableUs
Verapamil Hydrochloridetablet, extended release180 mg/1oralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs
Verapamil Hydrochloridetablet80 mg/1oralREMEDYREPACK INC.2011-08-08Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralTeva Pharmaceuticals USA Inc2014-04-07Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-02-23Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralUnit Dose Services2011-08-05Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralCardinal Health2012-07-12Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralGolden State Medical Supply, Inc2014-12-04Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralGlenmark Pharmaceuticals Inc., Usa2009-09-17Not applicableUs
Verapamil Hydrochloridetablet120 mg/1oralREMEDYREPACK INC.2011-12-13Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralA S Medication Solutions2009-09-17Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralClinical Solutions Wholesale2009-09-17Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralbryant ranch prepack1997-10-10Not applicableUs
Verapamil Hydrochloridetablet, film coated80 mg/1oralActavis Pharma, Inc.1986-10-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-09-17Not applicableUs
Verapamil Hydrochloridecapsule, extended release240 mg/1oralMylan Pharmaceuticals Inc.1999-05-19Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralRebel Distributors Corp2010-04-20Not applicableUs
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Verapamil Hydrochloridecapsule, extended release200 mg/1oralPhysicians Total Care, Inc.2010-05-17Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralPreferred Pharmaceuticals, Inc.2012-06-04Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralAphena Pharma Solutions Tennessee, Llc1996-03-25Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralMylan Pharmaceuticals Inc.1997-02-25Not applicableUs
Verapamil Hydrochloridetablet, film coated80 mg/1oralMajor Pharmaceuticals1986-10-01Not applicableUs
Verapamil Hydrochloridecapsule, extended release120 mg/1oralMylan Institutional Inc.1999-10-01Not applicableUs
Verapamil Hydrochloridetablet, film coated80 mg/1oralPhysicians Total Care, Inc.1995-04-24Not applicableUs
Verapamil Hydrochloridetablet, extended release240 mg/1oralREMEDYREPACK INC.2011-12-07Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralBlenheim Pharmacal, Inc.2013-12-17Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release180 mg/1oralPhysicians Total Care, Inc.1996-01-15Not applicableUs
Verapamil Hydrochloridetablet, extended release240 mg/1oralSun Pharmaceutical Industries, Inc.2012-01-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralbryant ranch prepack1992-08-01Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralGlenmark Pharmaceuticals Inc., Usa2011-08-05Not applicableUs
Verapamil Hydrochloridetablet, extended release180 mg/1oralPd Rx Pharmaceuticals, Inc.2012-01-01Not applicableUs
Verapamil Hydrochloridetablet, film coated80 mg/1oralMylan Pharmaceuticals Inc.2012-08-15Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-02-23Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralMylan Institutional Inc.1996-04-15Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release120 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousCardinal Health2011-03-25Not applicableUs
Verapamil Hydrochloridetablet, film coated, extended release240 mg/1oralGolden State Medical Supply, Inc2014-12-04Not applicableUs
Verapamil Hydrochloridetablet, film coated40 mg/1oralClinical Solutions Wholesale1993-06-29Not applicableUs
Verapamil Hydrochloridetablet, film coated120 mg/1oralActavis Pharma, Inc.1986-10-01Not applicableUs
Verapamil Hydrochloridetablet120 mg/1oralA S Medication Solutions Llc2011-01-07Not applicableUs
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousHospira, Inc.1987-05-06Not applicableUs
Verapamil Hydrochloridetablet80 mg/1oralHeritage Pharmaceuticals Inc.2011-01-07Not applicableUs
Verapamil Hydrochlorideinjection, solution2.5 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
Verapamil Hydrochloridetablet, film coated80 mg/1oralCardinal Health1986-10-01Not applicableUs
Verapamil Hydrochloride PMcapsule, extended release100 mg/1oralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs
Verapamil Hydrochloride PMcapsule, extended release100 mg/1oralAvera Mc Kennan Hospital2015-06-25Not applicableUs
Verapamil Hydrochloride PMcapsule, extended release200 mg/1oralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs
Verapamil Hydrochloride PMcapsule, extended release300 mg/1oralMylan Pharmaceuticals Inc.2007-08-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BosoptinBosnalijek
IsoptinAbbott
VerisopGerard
VerminRatiopharm
VerminePharmasant
VerogalidIvax
Verogalid ERIvax
VerpamilMylan
VertabTrinity-Chiesi
VetrimilCCPC
ZolveraRosemont
Brand mixtures
NameLabellerIngredients
TarkaAbb Vie Inc.
Trandolapril and Verapamil HydrochlorideGlenmark Pharmaceuticals Inc., Usa
Trandolapril and Verapamil Hydrochloride ERGreenstone LLC
Salts
Name/CASStructureProperties
Verapamil Hydrochloride
152-11-4
Thumb
  • InChI Key: DOQPXTMNIUCOSY-UHFFFAOYNA-N
  • Monoisotopic Mass: 490.259835453
  • Average Mass: 491.063
DBSALT000534
Categories
UNIICJ0O37KU29
CAS number52-53-9
WeightAverage: 454.6016
Monoisotopic: 454.283157714
Chemical FormulaC27H38N2O4
InChI KeyInChIKey=SGTNSNPWRIOYBX-UHFFFAOYSA-N
InChI
InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
IUPAC Name
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
SMILES
COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • O-dimethoxybenzene
  • Dimethoxybenzene
  • Phenylpropane
  • Phenethylamine
  • Benzyl-cyanide
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Tertiary aliphatic amine
  • Tertiary amine
  • Nitrile
  • Carbonitrile
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension, angina, and cluster headache prophylaxis.
PharmacodynamicsVerapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.
Mechanism of actionVerapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel subtypes are involved is presently not known.
Related Articles
Absorption90%
Volume of distributionNot Available
Protein binding90%
Metabolism
SubstrateEnzymesProduct
Verapamil
O-Desmethylverapamil (D-702)Details
Verapamil
Verapamil metabolite D-617Details
Verapamil
NorverapamilDetails
Verapamil
O-Desmethylverapamil (D-703)Details
O-Desmethylverapamil (D-702)
Verapamil metabolite D-620Details
Verapamil metabolite D-617
Verapamil metabolite D-620Details
Verapamil metabolite D-617
Not Available
Verapamil metabolite PR-25Details
Norverapamil
Verapamil metabolite D-715 (PR-22)Details
Norverapamil
Verapamil metabolite D-620Details
Route of eliminationApproximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.
Half life2.8-7.4 hours
ClearanceNot Available
ToxicityLD50=8 mg/kg (i.v. in mice)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Verapamil Action PathwayDrug actionSMP00375
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableG > CBetter response to drug therapy22192668
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9371
Blood Brain Barrier+0.6323
Caco-2 permeable+0.738
P-glycoprotein substrateSubstrate0.7874
P-glycoprotein inhibitor IInhibitor0.9056
P-glycoprotein inhibitor IIInhibitor0.855
Renal organic cation transporterInhibitor0.6259
CYP450 2C9 substrateNon-substrate0.8029
CYP450 2D6 substrateNon-substrate0.8706
CYP450 3A4 substrateSubstrate0.7657
CYP450 1A2 substrateNon-inhibitor0.9553
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9181
Ames testNon AMES toxic0.8393
CarcinogenicityNon-carcinogens0.6463
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4137 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7687
hERG inhibition (predictor II)Inhibitor0.8188
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Mylan pharmaceuticals inc
  • Elan drug delivery inc
  • Gd searle llc
  • Fsc laboratories inc
  • Abraxis pharmaceutical products
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Ranbaxy laboratories inc
  • Glenmark generics ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
  • Pliva inc
  • Actavis elizabeth llc
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tablet (extended-release)oral180 mg
Tabletoral80 mg
Tablet, film coatedoral120 mg/1
Tablet, film coatedoral80 mg/1
Tablet, film coated, extended releaseoral120 mg/1
Tablet, film coated, extended releaseoral180 mg/1
Tablet, film coated, extended releaseoral240 mg/1
Tablet, extended releaseoral180 mg/1
Tablet, extended releaseoral240 mg/1
Tabletoral120 mg
Tablet (extended-release)oral120 mg
Tablet (extended-release)oral240 mg
Tablet (extended-release)oral
Tablet, film coated, extended releaseoral
Capsule, extended releaseoral120 mg/1
Capsule, extended releaseoral180 mg/1
Capsule, extended releaseoral240 mg/1
Injectionintravenous2.5 mg/mL
Injection, solutionintravenous2.5 mg/mL
Tabletoral120 mg/1
Tabletoral240 mg/1
Tabletoral40 mg/1
Tabletoral80 mg/1
Tablet, extended releaseoral120 mg/1
Tablet, extended releaseoral240 mg/301
Tablet, film coatedoral40 mg/1
Solutionintravenous2.5 mg
Liquidintravenous2.5 mg
Capsule (sustained-release)oral120 mg
Capsule (sustained-release)oral180 mg
Capsule (sustained-release)oral240 mg
Capsule, delayed release pelletsoral120 mg/1
Capsule, delayed release pelletsoral180 mg/1
Capsule, delayed release pelletsoral240 mg/1
Capsule, delayed release pelletsoral360 mg/1
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral300 mg/1
Prices
Unit descriptionCostUnit
Verelan 360 mg 24 Hour Capsule6.82USD capsule
Verelan 360 mg cap pellet6.73USD pellet
Verelan pm 300 mg cap pellet5.87USD pellet
Verelan 240 mg 24 Hour Capsule4.76USD capsule
Verelan 240 mg cap pellet4.58USD pellet
Verelan 180 mg 24 Hour Capsule4.22USD capsule
Verelan 180 mg cap pellet4.06USD pellet
Verelan pm 200 mg cap pellet4.04USD pellet
Verelan 120 mg cap pellet3.87USD pellet
Verapamil HCl CR 300 mg 24 Hour Capsule3.82USD capsule
Isoptin sr 240 mg tablet3.32USD tablet
Verapamil hcl powder3.24USD g
Calan SR 240 mg Controlled Release Tabs3.15USD tab
Isoptin SR 240 mg Controlled Release Tabs3.14USD tab
Verelan pm 100 mg cap pellet3.13USD pellet
Calan sr 240 mg caplet3.09USD caplet
Covera-HS 240 mg 24 Hour tablet3.09USD tablet
Covera-hs 240 mg tablet sa2.97USD tablet
Isoptin sr 180 mg tablet2.9USD tablet
Calan SR 180 mg Controlled Release Tabs2.8USD tab
Isoptin SR 180 mg Controlled Release Tabs2.74USD tab
Calan sr 180 mg caplet2.7USD caplet
Verapamil HCl CR 200 mg 24 Hour Capsule2.62USD capsule
Isoptin sr 120 mg tablet2.29USD tablet
Calan SR 120 mg Controlled Release Tabs2.27USD tab
Covera-HS 180 mg 24 Hour tablet2.2USD tablet
Isoptin SR 120 mg Controlled Release Tabs2.16USD tab
Calan sr 120 mg caplet2.13USD caplet
Covera-hs 180 mg tablet sa2.11USD tablet
Verapamil HCl CR 360 mg 24 Hour Capsule2.1USD capsule
Verapamil HCl CR 100 mg 24 Hour Capsule2.04USD capsule
Isoptin Sr 240 mg Sustained-Release Tablet2.03USD tablet
Calan sr 240 mg caplet sa1.77USD caplet
Verapamil HCl CR 240 mg 24 Hour Capsule1.69USD capsule
Verapamil HCl CR 240 mg Controlled Release Tabs1.6USD tab
Calan 120 mg tablet1.56USD tablet
Isoptin Sr 180 mg Sustained-Release Tablet1.52USD tablet
Verapamil HCl CR 180 mg 24 Hour Capsule1.5USD capsule
Calan sr 180 mg caplet sa1.46USD caplet
Verapamil HCl CR 120 mg 24 Hour Capsule1.43USD capsule
Verapamil HCl CR 180 mg Controlled Release Tabs1.41USD tab
Isoptin Sr 120 mg Sustained-Release Tablet1.34USD tablet
Calan 80 mg tablet1.25USD tablet
Verapamil 2.5 mg/ml vial1.18USD ml
Verapamil HCl CR 120 mg Controlled Release Tabs1.12USD tab
Apo-Verap Sr 240 mg Sustained-Release Tablet0.91USD tablet
Mylan-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Novo-Veramil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Pms-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Calan 40 mg tablet0.76USD tablet
Apo-Verap Sr 120 mg Sustained-Release Tablet0.72USD tablet
Mylan-Verapamil Sr 120 mg Sustained-Release Tablet0.72USD tablet
Verapamil HCl 120 mg tablet0.71USD tablet
Apo-Verap Sr 180 mg Sustained-Release Tablet0.69USD tablet
Mylan-Verapamil Sr 180 mg Sustained-Release Tablet0.69USD tablet
Verapamil HCl 80 mg tablet0.56USD tablet
Apo-Verap 120 mg Tablet0.45USD tablet
Mylan-Verapamil 120 mg Tablet0.45USD tablet
Nu-Verap 120 mg Tablet0.45USD tablet
Verapamil 120 mg tablet0.39USD tablet
Verapamil 80 mg tablet0.31USD tablet
Verapamil HCl 40 mg tablet0.29USD tablet
Apo-Verap 80 mg Tablet0.29USD tablet
Mylan-Verapamil 80 mg Tablet0.29USD tablet
Nu-Verap 80 mg Tablet0.29USD tablet
Verapamil 40 mg tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5785994 No1992-10-222009-10-22Us
US6096339 No1997-04-042017-04-04Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point243-246 °C at 1.00E-02 mm HgPhysProp
water solubility4.47 mg/LNot Available
logP3.79HANSCH,C ET AL. (1995)
Caco2 permeability-4.58ADME Research, USCD
pKa8.92SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP5.23ALOGPS
logP5.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)9.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.95 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity132.65 m3·mol-1ChemAxon
Polarizability51.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-004l-0702900000-6a46ea2d5eed6d8b01ebView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0006-4109800000-80d342090a0be3344e82View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-054w-0954400000-2def387c7c93ab211423View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positivesplash10-0a4i-0000900000-4cde9a4b3a4f83d16afcView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positivesplash10-0a4i-0000900000-980b47834e505d54a0e6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positivesplash10-066r-0902800000-ae024239c46b33917426View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positivesplash10-014i-0901000000-81d1159b3102cff76218View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positivesplash10-014i-0900000000-d9c344fee7b45b4030e6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0gb9-0914000000-070bdb975910e9aae99cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-03di-0390000000-f41d80462c5d06c4f001View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0097-2980000000-9a2ab0bcab33f7eaac6bView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0uxr-0900000000-252a9989a8511cb2db80View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , Positivesplash10-0f79-0900000000-4fd6ca2c6c19c3bbf8f0View in MoNA
MSMass Spectrum (Electron Ionization)splash10-0udi-3519000000-b5e0b9e0caac5cb57222View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Philippe Baudier, Arthur De Boeck, Jacques Fossion, “Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms.” U.S. Patent US4859469, issued April, 1987.

US4859469
General References
  1. Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [PubMed:8725386 ]
External Links
ATC CodesC08DA51C09BB10C08DA01
AHFS Codes
  • 24:28.92
PDB EntriesNot Available
FDA labelDownload (1.9 MB)
MSDSDownload (73.5 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Verapamil.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Verapamil.
AbirateroneThe serum concentration of Verapamil can be increased when it is combined with Abiraterone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Verapamil.
AcebutololThe risk or severity of adverse effects can be increased when Verapamil is combined with Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Verapamil.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Verapamil.
AcetaminophenThe serum concentration of Verapamil can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Acetazolamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Verapamil.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Verapamil.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Verapamil.
AfatinibThe serum concentration of Verapamil can be increased when it is combined with Afatinib.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Verapamil.
AlbendazoleThe serum concentration of Verapamil can be increased when it is combined with Albendazole.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Verapamil.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Verapamil.
AlectinibThe serum concentration of Verapamil can be increased when it is combined with Alectinib.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Verapamil.
AlfentanilThe serum concentration of Verapamil can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Verapamil.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Verapamil.
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Verapamil.
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Verapamil.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Verapamil.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Verapamil.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Verapamil.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Verapamil.
AlosetronThe metabolism of Alosetron can be decreased when combined with Verapamil.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Verapamil.
AmantadineThe serum concentration of Verapamil can be increased when it is combined with Amantadine.
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Verapamil.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Verapamil.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Verapamil.
Aminohippuric acidThe serum concentration of Verapamil can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Verapamil.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Verapamil.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Verapamil.
AmiodaroneThe serum concentration of Verapamil can be decreased when it is combined with Amiodarone.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Verapamil.
AmitriptylineThe serum concentration of Verapamil can be increased when it is combined with Amitriptyline.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Verapamil.
AmobarbitalAmobarbital may increase the hypotensive activities of Verapamil.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Verapamil.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Verapamil.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Verapamil.
AmprenavirThe serum concentration of Verapamil can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Verapamil can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Verapamil is combined with Amyl Nitrite.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Verapamil.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Verapamil.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Verapamil.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Verapamil.
ApraclonidineThe risk or severity of adverse effects can be increased when Verapamil is combined with Apraclonidine.
ApremilastThe metabolism of Apremilast can be decreased when combined with Verapamil.
AprepitantThe serum concentration of Verapamil can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Verapamil.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Verapamil.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.
AripiprazoleAripiprazole may increase the hypotensive activities of Verapamil.
ArmodafinilThe metabolism of Verapamil can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Verapamil.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Verapamil.
ArtemetherThe metabolism of Artemether can be decreased when combined with Verapamil.
AsenapineThe metabolism of Asenapine can be decreased when combined with Verapamil.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Verapamil.
AstemizoleThe serum concentration of Verapamil can be increased when it is combined with Astemizole.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Verapamil.
AtazanavirThe serum concentration of Verapamil can be increased when it is combined with Atazanavir.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Verapamil.
AtomoxetineThe metabolism of Verapamil can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Verapamil.
AtorvastatinThe serum concentration of Verapamil can be increased when it is combined with Atorvastatin.
AtosibanThe risk or severity of adverse effects can be increased when Verapamil is combined with Atosiban.
Atracurium besylateVerapamil may increase the neuromuscular blocking activities of Atracurium besylate.
AvanafilThe metabolism of Avanafil can be decreased when combined with Verapamil.
AxitinibThe metabolism of Axitinib can be decreased when combined with Verapamil.
AzelastineThe metabolism of Azelastine can be decreased when combined with Verapamil.
AzelastineThe serum concentration of Verapamil can be increased when it is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Verapamil.
AzithromycinThe serum concentration of Verapamil can be increased when it is combined with Azithromycin.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Verapamil.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Verapamil.
BarbitalBarbital may increase the hypotensive activities of Verapamil.
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Verapamil.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Verapamil.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Verapamil.
BenzocaineThe serum concentration of Verapamil can be increased when it is combined with Benzocaine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Verapamil.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Verapamil.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Verapamil.
BepridilThe serum concentration of Verapamil can be increased when it is combined with Bepridil.
BeractantVerapamil may increase the bradycardic activities of Beractant.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Verapamil.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Verapamil.
BexaroteneThe serum concentration of Verapamil can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Verapamil.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Verapamil.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Verapamil.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Verapamil.
BiperidenThe serum concentration of Verapamil can be increased when it is combined with Biperiden.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Verapamil.
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Verapamil.
BortezomibThe metabolism of Verapamil can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Verapamil can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Verapamil.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Verapamil.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Verapamil.
BretyliumBretylium may increase the bradycardic activities of Verapamil.
BretyliumThe risk or severity of adverse effects can be increased when Verapamil is combined with Bretylium.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Verapamil.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Verapamil.
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Verapamil.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Verapamil.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Verapamil.
BromocriptineThe serum concentration of Verapamil can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Verapamil.
BudesonideThe metabolism of Budesonide can be decreased when combined with Verapamil.
BumetanideThe risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Verapamil.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Verapamil.
BuprenorphineThe serum concentration of Verapamil can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Verapamil.
BuspironeThe metabolism of Buspirone can be decreased when combined with Verapamil.
BuspironeThe serum concentration of Verapamil can be increased when it is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Verapamil.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Verapamil.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Verapamil.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Verapamil.
CabazitaxelThe serum concentration of Verapamil can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Verapamil.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Verapamil.
CaffeineThe metabolism of Caffeine can be decreased when combined with Verapamil.
CaffeineThe serum concentration of Verapamil can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Verapamil.
CalfactantVerapamil may increase the bradycardic activities of Calfactant.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Verapamil.
CanagliflozinThe risk or severity of adverse effects can be increased when Verapamil is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Verapamil.
CapecitabineThe metabolism of Verapamil can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Captopril.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Verapamil.
CarbamazepineThe serum concentration of Verapamil can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Verapamil.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Verapamil.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Verapamil.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Verapamil.
CarvedilolCarvedilol may increase the hypotensive activities of Verapamil.
CarvedilolThe risk or severity of adverse effects can be increased when Verapamil is combined with Carvedilol.
CaspofunginThe serum concentration of Verapamil can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Verapamil.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Verapamil.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Verapamil.
CeritinibVerapamil may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Verapamil can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Verapamil.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Verapamil.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Verapamil.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Verapamil.
ChloramphenicolThe metabolism of Verapamil can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Verapamil.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Verapamil.
ChloroquineThe serum concentration of Verapamil can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Verapamil.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Verapamil.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Verapamil.
ChlorpromazineThe serum concentration of Verapamil can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Verapamil can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Verapamil can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Verapamil.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Verapamil.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Verapamil.
CholesterolThe serum concentration of Verapamil can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Verapamil can be decreased when it is combined with Cholic Acid.
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Verapamil.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Verapamil.
CilazaprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Verapamil.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Verapamil.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Verapamil.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Verapamil.
CiprofloxacinThe serum concentration of Verapamil can be increased when it is combined with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Verapamil.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Verapamil.
CitalopramThe metabolism of Citalopram can be decreased when combined with Verapamil.
CitalopramThe serum concentration of Verapamil can be increased when it is combined with Citalopram.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Verapamil.
ClarithromycinThe serum concentration of Verapamil can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Verapamil can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Clevidipine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Verapamil.
ClobazamThe metabolism of Clobazam can be decreased when combined with Verapamil.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Verapamil.
ClofazimineThe serum concentration of Verapamil can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Verapamil.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Verapamil.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Verapamil.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Verapamil.
ClomipramineThe serum concentration of Verapamil can be increased when it is combined with Clomipramine.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Verapamil.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Verapamil.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.
ClopidogrelThe metabolism of Verapamil can be decreased when combined with Clopidogrel.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Verapamil.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Verapamil.
ClotrimazoleThe metabolism of Verapamil can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Verapamil.
CobicistatThe serum concentration of Verapamil can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Verapamil.
CocaineThe metabolism of Cocaine can be decreased when combined with Verapamil.
CodeineThe metabolism of Codeine can be decreased when combined with Verapamil.
ColchicineThe metabolism of Colchicine can be decreased when combined with Verapamil.
ColchicineThe serum concentration of Verapamil can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Verapamil can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Verapamil can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Verapamil.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Verapamil.
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Verapamil.
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Verapamil.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Verapamil.
CyclophosphamideThe serum concentration of Verapamil can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Verapamil can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Verapamil can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Verapamil.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Verapamil.
DabrafenibThe serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Verapamil.
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Verapamil.
DaclatasvirThe serum concentration of Verapamil can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Verapamil.
DactinomycinThe serum concentration of Verapamil can be increased when it is combined with Dactinomycin.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Verapamil.
DapagliflozinThe risk or severity of adverse effects can be increased when Verapamil is combined with Dapagliflozin.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Verapamil.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Verapamil.
DapsoneThe metabolism of Dapsone can be decreased when combined with Verapamil.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Verapamil.
DarunavirThe metabolism of Darunavir can be decreased when combined with Verapamil.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Verapamil.
DasatinibThe serum concentration of Verapamil can be increased when it is combined with Dasatinib.
DasatinibThe metabolism of Dasatinib can be decreased when combined with Verapamil.
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Verapamil.
DaunorubicinThe serum concentration of Verapamil can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Verapamil.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Verapamil.
DeferasiroxThe serum concentration of Verapamil can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe metabolism of Dehydroepiandrosterone can be decreased when combined with Verapamil.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Verapamil.
DesipramineThe serum concentration of Verapamil can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Verapamil can be increased when it is combined with Desloratadine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Verapamil.
DexamethasoneThe serum concentration of Verapamil can be decreased when it is combined with Dexamethasone.
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Verapamil.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Verapamil.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Verapamil.
DextromethorphanThe serum concentration of Verapamil can be increased when it is combined with Dextromethorphan.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Verapamil.
DiazepamThe metabolism of Diazepam can be decreased when combined with Verapamil.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Verapamil.
DiclofenacThe serum concentration of Verapamil can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Verapamil.
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Verapamil.
DigoxinThe metabolism of Digoxin can be decreased when combined with Verapamil.
DigoxinThe serum concentration of Verapamil can be decreased when it is combined with Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Verapamil.
DihydroergotamineThe metabolism of Verapamil can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Verapamil.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Verapamil.
DinutuximabThe risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Verapamil is combined with Dipyridamole.
DisopyramideThe risk or severity of adverse effects can be increased when Verapamil is combined with Disopyramide.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Verapamil.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Verapamil.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Verapamil.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Verapamil.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Verapamil.
DonepezilThe metabolism of Donepezil can be decreased when combined with Verapamil.
DonepezilDonepezil may increase the bradycardic activities of Verapamil.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Verapamil.
DoxazosinDoxazosin may increase the hypotensive activities of Verapamil.
DoxazosinThe risk or severity of adverse effects can be increased when Verapamil is combined with Doxazosin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Verapamil.
DoxepinThe serum concentration of Verapamil can be increased when it is combined with Doxepin.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Verapamil.
DoxorubicinThe serum concentration of Verapamil can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Verapamil can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Verapamil.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Verapamil.
DuloxetineVerapamil may increase the orthostatic hypotensive activities of Duloxetine.
DutasterideThe metabolism of Dutasteride can be decreased when combined with Verapamil.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Verapamil.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Verapamil.
EfavirenzThe serum concentration of Verapamil can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Verapamil.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Verapamil.
ElbasvirThe serum concentration of Verapamil can be increased when it is combined with Elbasvir.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Verapamil.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Verapamil.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Verapamil.
EmpagliflozinThe risk or severity of adverse effects can be increased when Verapamil is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Verapamil.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Verapamil.
EnzalutamideThe serum concentration of Verapamil can be increased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Verapamil.
EplerenoneThe risk or severity of adverse effects can be increased when Verapamil is combined with Eplerenone.
EprosartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Verapamil.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Verapamil.
ErgonovineThe serum concentration of Verapamil can be increased when it is combined with Ergonovine.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Verapamil.
ErgotamineThe serum concentration of Verapamil can be increased when it is combined with Ergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Verapamil.
ErythromycinThe metabolism of Verapamil can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Verapamil.
Eslicarbazepine acetateThe serum concentration of Verapamil can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Verapamil.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Verapamil.
EstazolamThe metabolism of Estazolam can be decreased when combined with Verapamil.
EstradiolThe metabolism of Estradiol can be decreased when combined with Verapamil.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Verapamil.
EstramustineThe metabolism of Estramustine can be decreased when combined with Verapamil.
EstramustineThe serum concentration of Verapamil can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Verapamil.
EstroneThe metabolism of Estrone can be decreased when combined with Verapamil.
EstroneThe serum concentration of Verapamil can be decreased when it is combined with Estrone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Verapamil.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Verapamil.
Etacrynic acidThe risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.
EthanolThe serum concentration of Ethanol can be increased when it is combined with Verapamil.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Verapamil.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Verapamil.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Verapamil.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Verapamil.
EtoposideThe metabolism of Etoposide can be decreased when combined with Verapamil.
EtoposideThe serum concentration of Verapamil can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Verapamil.
EtravirineThe serum concentration of Verapamil can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Verapamil.
EverolimusThe metabolism of Everolimus can be decreased when combined with Verapamil.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Verapamil.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Verapamil.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Verapamil.
FelbamateThe metabolism of Felbamate can be decreased when combined with Verapamil.
FelodipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Felodipine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Verapamil.
FentanylThe metabolism of Fentanyl can be decreased when combined with Verapamil.
FentanylThe serum concentration of Verapamil can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.
FexofenadineThe bioavailability of Fexofenadine can be increased when combined with Verapamil.
FexofenadineThe serum concentration of Verapamil can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Verapamil.
FidaxomicinThe serum concentration of Verapamil can be increased when it is combined with Fidaxomicin.
FinasterideThe metabolism of Finasteride can be decreased when combined with Verapamil.
FingolimodVerapamil may increase the bradycardic activities of Fingolimod.
FlecainideThe risk or severity of adverse effects can be increased when Verapamil is combined with Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Verapamil.
FloxuridineThe metabolism of Verapamil can be decreased when combined with Floxuridine.
FluconazoleThe serum concentration of Verapamil can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Verapamil.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Verapamil.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Verapamil.
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Verapamil.
FluorouracilThe metabolism of Verapamil can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Verapamil.
FluoxetineThe serum concentration of Verapamil can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Verapamil can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Verapamil can be increased when it is combined with Fluphenazine.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Verapamil.
FlurazepamThe serum concentration of Verapamil can be increased when it is combined with Flurazepam.
FlutamideThe metabolism of Flutamide can be decreased when combined with Verapamil.
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Verapamil.
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Verapamil.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Verapamil.
FluvoxamineThe metabolism of Verapamil can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Verapamil.
FosaprepitantThe serum concentration of Verapamil can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Verapamil.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Verapamil.
FosphenytoinThe metabolism of Verapamil can be increased when combined with Fosphenytoin.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Verapamil.
FurosemideThe risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.
Fusidic AcidThe serum concentration of Verapamil can be increased when it is combined with Fusidic Acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Verapamil.
GalantamineGalantamine may increase the bradycardic activities of Verapamil.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Verapamil.
GefitinibThe serum concentration of Verapamil can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Verapamil.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Verapamil.
GenisteinThe serum concentration of Verapamil can be increased when it is combined with Genistein.
GlipizideThe metabolism of Glipizide can be decreased when combined with Verapamil.
GlyburideThe metabolism of Glyburide can be decreased when combined with Verapamil.
GlyburideThe serum concentration of Verapamil can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Verapamil can be increased when it is combined with Glycerol.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Verapamil.
Gramicidin DThe serum concentration of Verapamil can be increased when it is combined with Gramicidin D.
GranisetronThe metabolism of Granisetron can be decreased when combined with Verapamil.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Verapamil.
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Verapamil.
GrepafloxacinThe serum concentration of Verapamil can be increased when it is combined with Grepafloxacin.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Verapamil.
GuanfacineThe risk or severity of adverse effects can be increased when Verapamil is combined with Guanfacine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Verapamil.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Verapamil.
HaloperidolThe serum concentration of Verapamil can be increased when it is combined with Haloperidol.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Verapamil.
HalothaneThe metabolism of Halothane can be decreased when combined with Verapamil.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Verapamil.
HexobarbitalHexobarbital may increase the hypotensive activities of Verapamil.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Verapamil.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Verapamil.
HydralazineThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Verapamil.
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Verapamil.
HydrocortisoneThe serum concentration of Verapamil can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Verapamil.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Verapamil.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Verapamil.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Verapamil.
IdelalisibThe serum concentration of Verapamil can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Verapamil.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Verapamil resulting in a loss in efficacy.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Verapamil.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Verapamil.
ImatinibThe metabolism of Verapamil can be decreased when combined with Imatinib.
ImipramineThe metabolism of Imipramine can be decreased when combined with Verapamil.
ImipramineThe serum concentration of Verapamil can be increased when it is combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Verapamil.
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Verapamil.
IndapamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Indapamide.
IndinavirThe metabolism of Indinavir can be decreased when combined with Verapamil.
IndinavirThe serum concentration of Verapamil can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Verapamil.
IndomethacinThe serum concentration of Verapamil can be increased when it is combined with Indomethacin.
IndoraminIndoramin may increase the hypotensive activities of Verapamil.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Verapamil.
IrbesartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Verapamil.
IsavuconazoniumThe metabolism of Verapamil can be decreased when combined with Isavuconazonium.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Verapamil.
IsoniazidThe metabolism of Verapamil can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Verapamil is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Verapamil.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Verapamil.
ItraconazoleThe serum concentration of Verapamil can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Verapamil.
IvabradineIvabradine may increase the bradycardic activities of Verapamil.
IvacaftorThe serum concentration of Verapamil can be increased when it is combined with Ivacaftor.
IvacaftorThe metabolism of Ivacaftor can be decreased when combined with Verapamil.
IvermectinThe metabolism of Ivermectin can be decreased when combined with Verapamil.
IvermectinThe serum concentration of Verapamil can be increased when it is combined with Ivermectin.
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Verapamil.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Verapamil.
KetamineThe metabolism of Ketamine can be decreased when combined with Verapamil.
KetamineThe serum concentration of Verapamil can be increased when it is combined with Ketamine.
KetazolamThe metabolism of Ketazolam can be decreased when combined with Verapamil.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Verapamil.
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Verapamil.
KetoconazoleThe serum concentration of Verapamil can be increased when it is combined with Ketoconazole.
LabetalolLabetalol may increase the hypotensive activities of Verapamil.
LabetalolThe risk or severity of adverse effects can be increased when Verapamil is combined with Labetalol.
LacosamideVerapamil may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Verapamil.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Verapamil.
LanreotideVerapamil may increase the bradycardic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Verapamil.
LansoprazoleThe serum concentration of Verapamil can be increased when it is combined with Lansoprazole.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Verapamil.
LapatinibThe serum concentration of Verapamil can be increased when it is combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Verapamil.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Verapamil.
LeflunomideThe metabolism of Verapamil can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Verapamil.
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Verapamil.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Verapamil.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Verapamil.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Verapamil.
LevobunololThe risk or severity of adverse effects can be increased when Verapamil is combined with Levobunolol.
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Verapamil.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Verapamil.
LevodopaVerapamil may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Verapamil.
LevofloxacinThe serum concentration of Verapamil can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Verapamil.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Verapamil.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Verapamil.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Verapamil.
LevothyroxineThe serum concentration of Verapamil can be decreased when it is combined with Levothyroxine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Verapamil.
LidocaineThe serum concentration of Verapamil can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Verapamil.
LiothyronineThe serum concentration of Verapamil can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Verapamil can be decreased when it is combined with Liotrix.
LisinoprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Verapamil.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Verapamil.
LoperamideThe metabolism of Loperamide can be decreased when combined with Verapamil.
LoperamideThe serum concentration of Verapamil can be increased when it is combined with Loperamide.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Verapamil.
LopinavirThe serum concentration of Verapamil can be increased when it is combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Verapamil.
LoratadineThe serum concentration of Verapamil can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Verapamil.
LosartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Losartan.
LovastatinThe metabolism of Verapamil can be decreased when combined with Lovastatin.
LucinactantVerapamil may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Verapamil can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Verapamil can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Verapamil.
LurasidoneThe metabolism of Lurasidone can be decreased when combined with Verapamil.
MacitentanThe metabolism of Macitentan can be decreased when combined with Verapamil.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Verapamil is combined with Mannitol.
MaprotilineThe serum concentration of Verapamil can be increased when it is combined with Maprotiline.
MaravirocThe metabolism of Maraviroc can be decreased when combined with Verapamil.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Verapamil.
MebendazoleThe serum concentration of Verapamil can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Verapamil.
MefloquineThe serum concentration of Verapamil can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Verapamil can be increased when it is combined with Megestrol acetate.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Verapamil.
MeprobamateThe serum concentration of Verapamil can be increased when it is combined with Meprobamate.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil.
MethadoneThe metabolism of Methadone can be decreased when combined with Verapamil.
MethadoneThe serum concentration of Verapamil can be increased when it is combined with Methadone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Verapamil.
MethazolamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Verapamil.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Verapamil.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Verapamil.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Verapamil.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.
MethyldopaThe risk or severity of adverse effects can be increased when Verapamil is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Verapamil.
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Verapamil.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Verapamil.
MetipranololThe risk or severity of adverse effects can be increased when Verapamil is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Verapamil.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Verapamil.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Verapamil.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Verapamil.
MianserinThe metabolism of Mianserin can be decreased when combined with Verapamil.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Verapamil.
MibefradilThe serum concentration of Verapamil can be increased when it is combined with Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Verapamil.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Verapamil.
MiconazoleThe serum concentration of Verapamil can be increased when it is combined with Miconazole.
MidazolamThe metabolism of Midazolam can be decreased when combined with Verapamil.
MidazolamThe serum concentration of Verapamil can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Verapamil.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Verapamil.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Verapamil.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Verapamil.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Verapamil.
MitomycinThe serum concentration of Verapamil can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Verapamil can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Verapamil.
MivacuriumVerapamil may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideThe metabolism of Verapamil can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Verapamil can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Verapamil.
MoexiprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Moexipril.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Verapamil.
MontelukastThe metabolism of Montelukast can be decreased when combined with Verapamil.
MorphineThe metabolism of Morphine can be decreased when combined with Verapamil.
MorphineThe serum concentration of Verapamil can be increased when it is combined with Morphine.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Verapamil.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Verapamil.
NadololThe risk or severity of adverse effects can be increased when Verapamil is combined with Nadolol.
NafcillinThe serum concentration of Verapamil can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Verapamil.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Verapamil.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Verapamil.
NaltrexoneThe serum concentration of Verapamil can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Verapamil can be increased when it is combined with Naringenin.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Verapamil.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Verapamil.
NebivololThe risk or severity of adverse effects can be increased when Verapamil is combined with Nebivolol.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Verapamil.
NefazodoneThe serum concentration of Verapamil can be decreased when it is combined with Nefazodone.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Verapamil.
NelfinavirThe serum concentration of Verapamil can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Verapamil can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Verapamil is combined with Nesiritide.
NetupitantThe serum concentration of Verapamil can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Verapamil can be decreased when combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Verapamil.
NicorandilNicorandil may increase the hypotensive activities of Verapamil.
NicotineThe metabolism of Nicotine can be decreased when combined with Verapamil.
NifedipineThe risk or severity of adverse effects can be increased when Verapamil is combined with Nifedipine.
NilotinibThe metabolism of Nilotinib can be decreased when combined with Verapamil.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Verapamil.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Verapamil.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Verapamil.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Verapamil.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Verapamil.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Verapamil.
NitrazepamThe serum concentration of Verapamil can be increased when it is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Verapamil.
NitrendipineThe serum concentration of Verapamil can be increased when it is combined with Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Verapamil is combined with Nitroglycerin.
NitroprussideVerapamil may increase the hypotensive activities of Nitroprusside.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Verapamil.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Verapamil.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Verapamil.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Verapamil.
NorethisteroneThe serum concentration of Verapamil can be decreased when it is combined with Norethisterone.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Verapamil.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Verapamil.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Verapamil.
OctreotideOctreotide may increase the bradycardic activities of Verapamil.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Verapamil.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Verapamil.
OlaparibThe metabolism of Verapamil can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Verapamil.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Verapamil.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Verapamil.
OmeprazoleThe serum concentration of Verapamil can be increased when it is combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Verapamil.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Verapamil.
OsimertinibThe serum concentration of Verapamil can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Verapamil.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Verapamil.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Verapamil.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Verapamil.
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Verapamil.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Verapamil.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Verapamil.
P-NitrophenolThe serum concentration of Verapamil can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Verapamil.
PaclitaxelThe serum concentration of Verapamil can be increased when it is combined with Paclitaxel.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Verapamil.
PalbociclibThe serum concentration of Verapamil can be increased when it is combined with Palbociclib.
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Verapamil.
Palmitic AcidThe serum concentration of Verapamil can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Verapamil.
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Verapamil.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Verapamil.
PantoprazoleThe serum concentration of Verapamil can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Verapamil.
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Verapamil.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Verapamil.
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Verapamil.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Verapamil.
ParoxetineThe serum concentration of Verapamil can be increased when it is combined with Paroxetine.
PasireotideVerapamil may increase the bradycardic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Verapamil.
Peginterferon alfa-2bThe serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.
PenbutololThe risk or severity of adverse effects can be increased when Verapamil is combined with Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Verapamil.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Verapamil.
PentobarbitalPentobarbital may increase the hypotensive activities of Verapamil.
PerampanelThe metabolism of Perampanel can be decreased when combined with Verapamil.
PergolideThe metabolism of Pergolide can be decreased when combined with Verapamil.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Verapamil.
PerindoprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Verapamil.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Verapamil.
PethidineThe metabolism of Pethidine can be decreased when combined with Verapamil.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Verapamil.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Verapamil.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Verapamil.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Verapamil.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Verapamil.
PhenytoinThe metabolism of Verapamil can be increased when combined with Phenytoin.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Verapamil.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Verapamil.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Verapamil.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Verapamil.
PindololThe risk or severity of adverse effects can be increased when Verapamil is combined with Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Verapamil.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Verapamil.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Verapamil.
Platelet Activating FactorThe serum concentration of Verapamil can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Verapamil.
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Verapamil.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Verapamil.
PonatinibThe serum concentration of Verapamil can be increased when it is combined with Ponatinib.
Poractant alfaVerapamil may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Verapamil.
PosaconazoleThe serum concentration of Verapamil can be increased when it is combined with Posaconazole.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Verapamil.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Verapamil.
PravastatinThe serum concentration of Verapamil can be increased when it is combined with Pravastatin.
PrazepamThe metabolism of Prazepam can be decreased when combined with Verapamil.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Verapamil.
PrazosinPrazosin may increase the hypotensive activities of Verapamil.
PrazosinThe risk or severity of adverse effects can be increased when Verapamil is combined with Prazosin.
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Verapamil.
PrednisoneThe metabolism of Prednisone can be decreased when combined with Verapamil.
PrednisoneThe serum concentration of Verapamil can be increased when it is combined with Prednisone.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Verapamil.
PrimidonePrimidone may increase the hypotensive activities of Verapamil.
ProbenecidThe serum concentration of Verapamil can be increased when it is combined with Probenecid.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Verapamil.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Verapamil.
ProgesteroneThe serum concentration of Verapamil can be decreased when it is combined with Progesterone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Verapamil.
PromazineThe metabolism of Promazine can be decreased when combined with Verapamil.
PromethazineThe serum concentration of Verapamil can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Verapamil.
PropofolThe metabolism of Propofol can be decreased when combined with Verapamil.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Verapamil.
ProtriptylineThe serum concentration of Verapamil can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Verapamil.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Verapamil.
PyrimethamineThe metabolism of Verapamil can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Verapamil can be increased when it is combined with Quazepam.
QuazepamThe metabolism of Quazepam can be decreased when combined with Verapamil.
QuercetinThe serum concentration of Verapamil can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Verapamil is combined with Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Verapamil.
QuinacrineThe serum concentration of Verapamil can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Quinapril.
QuinidineQuinidine may increase the hypotensive activities of Verapamil.
QuinidineThe metabolism of Quinidine can be decreased when combined with Verapamil.
QuinineThe metabolism of Quinine can be decreased when combined with Verapamil.
QuinineThe serum concentration of Verapamil can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Verapamil.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Verapamil.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Verapamil.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Verapamil.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Verapamil.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Verapamil.
RanitidineThe serum concentration of Verapamil can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Verapamil.
RapacuroniumVerapamil may increase the neuromuscular blocking activities of Rapacuronium.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Verapamil.
ReboxetineThe serum concentration of Verapamil can be increased when it is combined with Reboxetine.
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Verapamil.
RegorafenibThe serum concentration of Verapamil can be increased when it is combined with Regorafenib.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Verapamil.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Verapamil.
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Verapamil.
RifabutinThe metabolism of Verapamil can be increased when combined with Rifabutin.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Verapamil.
RifampicinThe serum concentration of Verapamil can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Verapamil can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Verapamil.
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Verapamil.
RilpivirineThe serum concentration of Verapamil can be increased when it is combined with Rilpivirine.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Verapamil.
RiociguatThe risk or severity of adverse effects can be increased when Verapamil is combined with Riociguat.
RisperidoneVerapamil may increase the hypotensive activities of Risperidone.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Verapamil.
RitonavirThe serum concentration of Verapamil can be decreased when it is combined with Ritonavir.
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Verapamil.
RivastigmineVerapamil may increase the bradycardic activities of Rivastigmine.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Verapamil.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Verapamil.
RolapitantThe serum concentration of Verapamil can be increased when it is combined with Rolapitant.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Verapamil.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Verapamil.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Verapamil.
RosiglitazoneThe metabolism of Verapamil can be decreased when combined with Rosiglitazone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Verapamil.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Verapamil.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Verapamil.
RuxolitinibRuxolitinib may increase the bradycardic activities of Verapamil.
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Verapamil.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Verapamil.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Verapamil.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Verapamil.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Verapamil.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Verapamil.
SaquinavirThe serum concentration of Verapamil can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Verapamil.
ScopolamineThe serum concentration of Verapamil can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Verapamil.
SelegilineThe metabolism of Selegiline can be decreased when combined with Verapamil.
SelegilineThe serum concentration of Verapamil can be increased when it is combined with Selegiline.
SelexipagThe metabolism of Selexipag can be decreased when combined with Verapamil.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Verapamil.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Verapamil.
SertindoleThe metabolism of Sertindole can be decreased when combined with Verapamil.
SertralineThe metabolism of Sertraline can be decreased when combined with Verapamil.
SertralineThe serum concentration of Verapamil can be increased when it is combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Verapamil.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Verapamil.
SildenafilThe metabolism of Verapamil can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Verapamil.
SilodosinSilodosin may increase the hypotensive activities of Verapamil.
SiltuximabThe serum concentration of Verapamil can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Verapamil can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Verapamil.
SimvastatinThe serum concentration of Verapamil can be increased when it is combined with Simvastatin.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Verapamil.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Verapamil.
SirolimusThe serum concentration of Verapamil can be decreased when it is combined with Sirolimus.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Verapamil.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Verapamil.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Verapamil.
SonidegibThe metabolism of Sonidegib can be decreased when combined with Verapamil.
SorafenibThe metabolism of Sorafenib can be decreased when combined with Verapamil.
SorafenibThe serum concentration of Verapamil can be increased when it is combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Verapamil.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Verapamil.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Verapamil.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Verapamil.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Verapamil.
St. John's WortThe serum concentration of Verapamil can be decreased when it is combined with St. John&#39;s Wort.
StaurosporineThe serum concentration of Verapamil can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Verapamil can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Verapamil can be decreased when it is combined with Streptozocin.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Verapamil.
SufentanilSufentanil may increase the bradycardic activities of Verapamil.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Verapamil.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Verapamil.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Verapamil.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Verapamil.
SulfinpyrazoneThe serum concentration of Verapamil can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Verapamil can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Verapamil can be increased when it is combined with Sumatriptan.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Verapamil.
SunitinibThe serum concentration of Verapamil can be increased when it is combined with Sunitinib.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Verapamil.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Verapamil.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Verapamil.
TacrineThe serum concentration of Verapamil can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Verapamil.
TacrolimusThe serum concentration of Verapamil can be decreased when it is combined with Tacrolimus.
TadalafilThe metabolism of Tadalafil can be decreased when combined with Verapamil.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Verapamil.
TamoxifenThe serum concentration of Verapamil can be decreased when it is combined with Tamoxifen.
TamsulosinTamsulosin may increase the hypotensive activities of Verapamil.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Verapamil.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Verapamil.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Verapamil.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Verapamil.
Taurocholic AcidThe serum concentration of Verapamil can be increased when it is combined with Taurocholic Acid.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Verapamil.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Verapamil.
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Verapamil.
TelithromycinTelithromycin may increase the bradycardic activities of Verapamil.
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Verapamil.
TelmisartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Verapamil.
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Verapamil.
TemsirolimusThe serum concentration of Verapamil can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be decreased when combined with Verapamil.
TenofovirThe metabolism of Verapamil can be decreased when combined with Tenofovir.
TerazosinTerazosin may increase the hypotensive activities of Verapamil.
TerazosinThe risk or severity of adverse effects can be increased when Verapamil is combined with Terazosin.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Verapamil.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Verapamil.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Verapamil.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Verapamil.
TerfenadineThe serum concentration of Verapamil can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Verapamil.
TesmilifeneThe serum concentration of Verapamil can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Verapamil.
TestosteroneThe serum concentration of Verapamil can be increased when it is combined with Testosterone.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Verapamil.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Verapamil.
ThiamylalThiamylal may increase the hypotensive activities of Verapamil.
ThiopentalThiopental may increase the hypotensive activities of Verapamil.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Verapamil.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Verapamil.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Verapamil.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Verapamil.
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Verapamil.
TicagrelorThe serum concentration of Verapamil can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Verapamil can be decreased when combined with Ticlopidine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Verapamil.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Verapamil.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Verapamil.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Verapamil.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Verapamil.
TizanidineThe risk or severity of adverse effects can be increased when Verapamil is combined with Tizanidine.
TocilizumabThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Verapamil.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Verapamil.
TolbutamideThe metabolism of Verapamil can be decreased when combined with Tolbutamide.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Verapamil.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Verapamil.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Verapamil.
TopiramateThe metabolism of Verapamil can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Verapamil.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.
ToremifeneThe metabolism of Toremifene can be decreased when combined with Verapamil.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Verapamil.
TramadolThe metabolism of Tramadol can be decreased when combined with Verapamil.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Verapamil.
TranylcypromineThe metabolism of Verapamil can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Verapamil.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Verapamil.
TrazodoneThe serum concentration of Verapamil can be decreased when it is combined with Trazodone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Verapamil.
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Verapamil.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Verapamil.
TriazolamThe metabolism of Triazolam can be decreased when combined with Verapamil.
TrifluoperazineThe serum concentration of Verapamil can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Verapamil can be increased when it is combined with Triflupromazine.
TrimazosinTrimazosin may increase the hypotensive activities of Verapamil.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Verapamil.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Verapamil.
TrimethoprimThe serum concentration of Verapamil can be decreased when it is combined with Trimethoprim.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Verapamil.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Verapamil.
TrimipramineThe serum concentration of Verapamil can be increased when it is combined with Trimipramine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Verapamil.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Verapamil.
TroleandomycinThe serum concentration of Verapamil can be increased when it is combined with Troleandomycin.
UdenafilThe metabolism of Udenafil can be decreased when combined with Verapamil.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Verapamil.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Verapamil.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Verapamil.
Valproic AcidThe metabolism of Verapamil can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Verapamil.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Verapamil.
VardenafilThe metabolism of Vardenafil can be decreased when combined with Verapamil.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Verapamil.
VemurafenibThe serum concentration of Verapamil can be increased when it is combined with Vemurafenib.
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Verapamil.
VenlafaxineThe metabolism of Verapamil can be decreased when combined with Venlafaxine.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Verapamil.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Verapamil.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Verapamil.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Verapamil.
VinblastineThe serum concentration of Verapamil can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Verapamil.
VincristineThe serum concentration of Verapamil can be decreased when it is combined with Vincristine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Verapamil.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Verapamil.
VinorelbineThe serum concentration of Verapamil can be increased when it is combined with Vinorelbine.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Verapamil.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Verapamil.
WarfarinThe metabolism of Warfarin can be decreased when combined with Verapamil.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Verapamil.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Verapamil.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Verapamil.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Verapamil.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Verapamil.
ZileutonThe metabolism of Zileuton can be decreased when combined with Verapamil.
ZimelidineThe serum concentration of Verapamil can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Verapamil can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Verapamil.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Verapamil.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Verapamil.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Verapamil.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid natural licorice.
  • Avoid taking with grapefruit juice.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Dilmac N, Hilliard N, Hockerman GH: Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol. 2004 Nov;66(5):1236-47. Epub 2004 Jul 30. [PubMed:15286207 ]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638 ]
  3. Patel MK, Clunn GF, Lymn JS, Austin O, Hughes AD: Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells. Br J Pharmacol. 2005 Jul;145(6):811-7. [PubMed:15880143 ]
  4. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1F
Uniprot ID:
O60840
Molecular Weight:
220675.9 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB1
Uniprot ID:
Q02641
Molecular Weight:
65712.995 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB3
Uniprot ID:
P54284
Molecular Weight:
54531.425 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB4
Uniprot ID:
O00305
Molecular Weight:
58168.625 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. Isoform alpha-1I gives rise to T-type calcium currents. T-type calcium channels belong to the "low-volta...
Gene Name:
CACNA1I
Uniprot ID:
Q9P0X4
Molecular Weight:
245100.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Freeze BS, McNulty MM, Hanck DA: State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel. Mol Pharmacol. 2006 Aug;70(2):718-26. Epub 2006 May 12. [PubMed:16699084 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1B gives rise to N-type calcium currents. N-type calcium channels belong to the 'high-...
Gene Name:
CACNA1B
Uniprot ID:
Q00975
Molecular Weight:
262493.84 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to...
Gene Name:
CACNA1A
Uniprot ID:
O00555
Molecular Weight:
282362.39 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN: Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007 Jul;28(7):959-67. [PubMed:17588331 ]
  2. Cheng HC, Incardona J, McCullough B: Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval. J Pharmacol Toxicol Methods. 2006 Nov-Dec;54(3):278-87. Epub 2006 Feb 28. [PubMed:16507347 ]
  3. Schneider J, Hauser R, Andreas JO, Linz K, Jahnel U: Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol. 2005 Apr 4;512(1):53-60. [PubMed:15814090 ]
  4. Ridley JM, Dooley PC, Milnes JT, Witchel HJ, Hancox JC: Lidoflazine is a high affinity blocker of the HERG K(+)channel. J Mol Cell Cardiol. 2004 May;36(5):701-5. [PubMed:15135665 ]
  5. Shimizu W, Aiba T, Antzelevitch C: Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. Curr Pharm Des. 2005;11(12):1561-72. [PubMed:15892662 ]
  6. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Milberg P, Reinsch N, Osada N, Wasmer K, Monnig G, Stypmann J, Breithardt G, Haverkamp W, Eckardt L: Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol. 2005 Jul;100(4):365-71. Epub 2005 Jun 10. [PubMed:15944809 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectific...
Gene Name:
KCNJ11
Uniprot ID:
Q14654
Molecular Weight:
43540.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Yamada S, Kane GC, Behfar A, Liu XK, Dyer RB, Faustino RS, Miki T, Seino S, Terzic A: Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol. 2006 Dec 15;577(Pt 3):1053-65. Epub 2006 Oct 12. [PubMed:17038430 ]
  3. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther. 2007 Jul;322(1):1-7. Epub 2007 Apr 4. [PubMed:17409272 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  2. Brown NL, Sirugue O, Worcel M: The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. [PubMed:2940099 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301 ]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  3. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
  4. Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y: Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000 Oct;28(10):1238-43. [PubMed:10997946 ]
  5. Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine. Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4. [PubMed:11031728 ]
  6. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287 ]
  7. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  8. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143 ]
  9. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  10. Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003 Mar;304(3):1258-67. [PubMed:12604704 ]
  11. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153 ]
  12. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  13. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. [PubMed:11042226 ]
  14. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
  15. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [PubMed:11454724 ]
  16. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
  17. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. [PubMed:7945455 ]
  18. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. [PubMed:8094615 ]
  19. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059 ]
  20. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. [PubMed:9205004 ]
  21. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409 ]
  22. Bebawy M, Morris MB, Roufogalis BD: A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem. 1999 Mar 15;268(2):270-7. [PubMed:10075817 ]
  23. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141 ]
  24. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6. [PubMed:10571255 ]
  25. Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52. [PubMed:10583025 ]
  26. Choi CH, Kim JH, Kim SH: Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR. Biochem Biophys Res Commun. 2004 Jul 30;320(3):672-9. [PubMed:15240100 ]
  27. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753 ]
  28. Hu K, Morris ME: Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci. 2004 Jul;93(7):1901-11. [PubMed:15176077 ]
  29. Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE, Choi SU: Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81. [PubMed:12569305 ]
  30. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  31. Petri N, Tannergren C, Rungstad D, Lennernas H: Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004 Aug;21(8):1398-404. [PubMed:15359574 ]
  32. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
  33. Santoni-Rugiu E, Silverman JA: Functional characterization of the rat mdr1b encoded P-glycoprotein: not all inducing agents are substrates. Carcinogenesis. 1997 Nov;18(11):2255-63. [PubMed:9395229 ]
  34. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078 ]
  35. Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, Sheu GT: L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18. doi: 10.1016/j.toxlet.2009.11.018. Epub 2009 Nov 26. [PubMed:19944135 ]
  36. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13. [PubMed:20071452 ]
  37. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272 ]
  38. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439 ]
  39. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926 ]
  40. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
  41. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
  42. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF: Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82. [PubMed:10773005 ]
  43. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  44. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  45. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  46. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
  47. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. [PubMed:14698039 ]
  48. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716 ]
  49. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340 ]
  50. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927 ]
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
  2. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M: Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79. Epub 2005 Dec 27. [PubMed:16384552 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
  2. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004 Jun;65(6):1485-95. [PubMed:15155841 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12. [PubMed:19139163 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 01, 2016 02:22